AHA In Brief: NeoRx Biostent
This article was originally published in The Gray Sheet
Executive Summary
NeoRx Biostent: Initial clinical results with cytochalasin B drug/catheter combination product find that 20% of patients with the treatment (six of 30) experienced post-procedure clinical events such as myocardial infarction, death, or revascularization, compared to 38% (five of 13) patients receiving a placebo, researchers report at the AHA conference in Orlando. Results were reported by Robert Wilensky, MD, University of Pennsylvania. A Phase II, 350-patient study is expected to begin in the second quarter of 1998, the company says. NeoRx is developing Biostent in collaboration with Schwarz Pharma A.G...
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.